Abstract：
In this study, a bovine serum albumin-decorated zeolitic imidazolate framework (ZIF-8@BSA) was used to enhance the anticancer and antimetastatic properties of methotrexate. SEM, DLS, FT-IR, and XRD confirmed the physicochemical suitability of the developed nanoparticles. According to the SEM analysis, the mean size of ZIF-8 nanoparticles was 68.5 ± 13.31 nm. The loading capacity and encapsulation efficiency of MTX@ZIF-8@BSA were 28.77 ± 2.54% and 96.3 ± 0.67%, respectively. According to the in vitro hemolysis test, MTX@ZIF-8@BSA showed excellent blood compatibility. MTX@ZIF-8@BSA exhibited pH sensitivity, releasing more MTX at pH 5.4 (1.73 times) than at pH 7.4. The IC50 value of MTX@ZIF-8@BSA on 4T1 cells was 32.7 ± 7.3 µg/mL after 48 h of treatment, outperforming compared to free MTX with an IC50 value of 53.3 ± 3.7 µg/mL. Treatment with MTX@ZIF-8@BSA resulted in superior tumor growth suppression in tumor-bearing mice than free MTX. Furthermore, based on histopathology tests, MTX@ZIF-8@BSA reduced the metastasis in lung and liver tissues. While there was not any noticeable toxicity in the vital organs of MTX@ZIF-8@BSA-receiving mice, free methotrexate resulted in severe toxicity in the kidneys and liver. According to the preliminary in vitro and in vivo findings, MTX@ZIF-8@BSA presents an attractive drug delivery system candidate for breast cancer due to its enhanced antitumor efficacy and lower toxicity.
摘要：
在这项研究中,牛血清白蛋白修饰的沸石咪唑酯框架（ZIF-8@BSA）用于增强甲氨蝶呤的抗癌和抗转移特性。SEM,DLS,FT-IR,和XRD证实了所开发的纳米颗粒的物理化学适用性。根据SEM分析,ZIF-8纳米颗粒的平均尺寸为68.5±13.31nm。MTX@ZIF-8@BSA的负载能力和包封效率分别为28.77±2.54%和96.3±0.67%,分别。根据体外溶血试验，MTX@ZIF-8@BSA表示出优越的血液相容性。MTX@ZIF-8@BSA表现出pH敏感性，在pH5.4时释放的MTX比在pH7.4时释放的MTX多（1.73倍）。处理48小时后，MTX@ZIF-8@BSA对4T1细胞的IC50值为32.7±7.3µg/mL，与游离MTX相比表现优异，IC50值为53.3±3.7µg/mL。与游离MTX相比,用MTX@ZIF-8@BSA治疗在荷瘤小鼠中产生优异的肿瘤生长抑制。此外，根据组织病理学检查,MTX@ZIF-8@BSA减少了肺和肝组织中的转移。虽然在接受MTX@ZIF-8@BSA的小鼠的重要器官中没有任何明显的毒性，游离甲氨蝶呤对肾脏和肝脏造成严重毒性.根据体外和体内的初步发现，MTX@ZIF-8@BSA由于其增强的抗肿瘤功效和较低的毒性而成为乳腺癌的有吸引力的候选药物递送系统。
